A diagnosis of uveal melanoma during pregnancy forces an agonising question: treat now, or wait? Dr Emine Kiliç chairs a multidisciplinary discussion with Dr Iwona Rospond-Kubiak (Poznań), Prof. Antonia Joussen (Charité, Berlin) and radiation oncologist Dr Adam Chicheł on plaque brachytherapy and fetal radiation exposure, how gestational age shapes timing, and the reassuring — if limited — evidence on placental spread and maternal survival.

Euretina will shortly relaunch the Women in Retina survey, building on the first dataset. In this podcast, Prof. Anat Loewenstein, Dr Federica Fossataro and Prof. Nicole Eter explore what has changed since the original 2021 study, what's new and why participation from the whole community - women and men alike - is essential to measuring real progress. The Women In Retina Initiative is sponsored by Bayer.

New therapies are reshaping geographic atrophy—but are trial endpoints keeping pace with clinical reality? Anat Loewenstein is joined by Sobha Sivaprasad and Kristina Pfau to examine how success in GA is measured, from lesion growth to functional vision. The panel explores microperimetry, contrast sensitivity, and emerging tools that may better reflect meaningful patient outcomes.

A landmark Phase 3 trial has delivered the first positive result for Stargardt disease treatment — but the therapeutic landscape is shifting fast. Prof. Maximilian Pfau enjoys a discussion with Prof. Carel Hoyng and Dr. Karolina Kaminska on the ABCA4 disease spectrum, the groundbreaking discovery of AP5 complex-related macular dystrophy, and emerging therapies from oral drugs to gene-specific approaches

Three former mentees of the EURETINA Mentorship Programme share how the initiative helped shape their careers in retinal research and clinical practice. Özge Yanık Odabaş, Karolina Motloch and Omer Trivizki discuss mentorship, international collaboration, and the opportunities created through the programme’s growing alumni network. Their experiences highlight how structured mentorship can accelerate professional development for the next generation of retina specialists

Artificial intelligence is rapidly reshaping retina care — but where does it truly add value in daily practice? Professors Tien Wong and Daniel Ting join Stela Vujosevic to explore how AI is moving beyond screening into risk stratification, clinical decision support, and home monitoring. From infrastructure challenges to real-world implementation, this episode offers practical insights for retina specialists preparing for an AI-enabled future

Artificial intelligence is rapidly reshaping how we screen, classify, and treat diabetic retinal disease. Professor Aude Couturier, Professor Edoardo Midena, and Professor Reinier Schlingemann discuss real-world AI applications in diabetic retinopathy — from population screening and imaging biomarkers to phenotyping and precision treatment in diabetic macular oedema

What drives leading retina specialists to trade the clinic for corporate innovation? In this episode, Euretina Board member Kourous Rezaei speaks with Jay Duker (CEO, Eyepoint), Sascha Fauser (SVP, Roche), and Marion Munk (CSO, Gutblick Group; CMO, Isarna Therapeutics) about their transitions from clinical practice to industry. Together they share insights on leadership, research, and the evolving relationship between academia and biotechnology in shaping the future of retinal therapeutics

In this episode Professors Dean Eliott, Grazia Pertile, and José García-Arumí join chair Kourous Rezaei to explore how surgical mastery is built through intuition, preparation, and reflection. They share practical insights on mentorship, focus, teamwork, and managing stressful cases — from avoiding coffee before surgery to resetting after complications — revealing that great surgeons are defined not just by skill, but by judgment, patience, and care for the patient

In this first-ever debate edition of Talking Euretina, Dr Rumana Hussain (Liverpool Ocular Oncology Centre) introduces Professors Arun Singh (Cole Eye Institute, Cleveland Clinic), Heinrich Heimann (Liverpool Ocular Oncology Service) and Bertil Damato (Moorfields Eye Hospital) as they debate one of ocular oncology’s most enduring questions — when to operate on small choroidal melanomas. The panel examines diagnostic uncertainty, genetic risk and patient choice in determining when to treat.